Maintenance therapies in bipolar disorder: focus on randomized controlled trials

References

• Murray C J, Lopez A D. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 1997; 349: 1436–1442
   PubMed Web of Science ®Google Scholar
• Denicoff K D, Smith-Jackson E E, Disney E R, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. Journal of Clinical Psychiatry 1997; 58: 470–478
   PubMed Web of Science ®Google Scholar
• O'Connell R A, Mayo J A, Flatow, et al. Outcome of bipolar disorder on long-term treatment with lithium. British Journal of Psychiatry 1991; 159: 123–129
   PubMed Web of Science ®Google Scholar
• Lambert P A, Cavaz G, Borselli S, Carbel S. [Action neuropschotrope d'un novel antiepileptique: le Depamide]. Annals of Medical Psychology 1966; 1: 707–710
   Google Scholar
• Ballenger J C, Post R M. Therapeutic effects of carbamazepine in affective illness: a preliminary report. Communications in Psychopharmacology 1978; 2: 159–175
   PubMedGoogle Scholar
• Calabrese J R, Rapport D J, Shelton M D, Kemmel S E. Evolving methodologies in bipolar disorder maintenance research. British Journal of Psychiatry 2001; 178(Suppl 41)s157–s163
   Google Scholar
• Baastrup P C, Poulsen J, Schou M, et al. Prophylactic lithium: double-blind discontinuation in manic-depressive and recurrent depressive disorders. Lancet 1970; 2: 326–330
   PubMedGoogle Scholar
• Melia P I. Prophylactic lithium: a double-blind trial in recurrent affective disorders. British Journal of Psychiatry 1970; 116: 621–624
   PubMedGoogle Scholar
• Coppen A, Noguera R, Bailey J, et al. Prophylactic lithium in affective disorders: controlled trial. Lancet 1971; 2: 275–279
   PubMed Web of Science ®Google Scholar
• Cundall R L, Brooks P, Murray L G. A controlled evaluation of lithium prophylaxis in affective disorders. Psychological Medicine 1972; 2: 308–311
   PubMed Web of Science ®Google Scholar
• Hullin R P, McDonald R, Allsopp M N. Prophylactic lithium in recurrent affective disorders. Lancet 1972; 11: 1044–1046
   Google Scholar
• Stallone F, Shelley E, Mendlewicz J, Fieve R R. The use of lithium in affective disorders: a double-blind study of prophylaxis in bipolar illness. American Journal of Psychiatry 1973; 130: 1006–1010
   PubMed Web of Science ®Google Scholar
• Prien R F, Caffey E M, Jr, Klett C J. Prophylactic efficacy of lithium carbonate in manic-depressive illness. Archives of General Psychiatry 1973; 28: 334–337
   Google Scholar
• Prien R F, Klett C J, Caffey E M, Jr. Lithium carbonate and imipramine in prevention of affective episodes: a comparison in recurrent affective illness. Archives of General Psychiatry 1973; 29: 420–425
   PubMed Web of Science ®Google Scholar
• Baldessarini R J, Tondo L, Hennen J, Viguera A C. Is lithium still worth using? An update of selected recent research. Harvard Review of Psychiatry 2002; 10: 59–75
   PubMed Web of Science ®Google Scholar
• Suppes T, Baldessarini R J, Faedda G L, et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Archives of General Psychiatry 1991; 48: 1082–1088
   PubMed Web of Science ®Google Scholar
• Geddes J R, Burgess S, Hawton K, Jamison K, Goodwin G M. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. American Journal of Psychiatry 2004; 161: 217–222
   PubMedGoogle Scholar
• Davis J M, Janicak P G, Hogan D M. Mood stabilizers in the prevention of recurrent affective disorder: a meta-analysis. Acta Psychiatrica Scandinavica 1999; 100: 406–417
   PubMed Web of Science ®Google Scholar
• Gelenberg A J, Kane J M, Keller M B, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. New England Journal of Medicine 1989; 321: 1489–1493
   PubMed Web of Science ®Google Scholar
• Harrow M, Goldberg J F, Grossman L S, Meltzer H Y. Outcome in manic disorders. Archives of General Psychiatry 1990; 47: 665–671
   PubMed Web of Science ®Google Scholar
• Coryell W, Winokur G, Solomon D, et al. Lithium and recurrence in a long-term follow-up of bipolar affective disorder. Psychological Medicine 1997; 27: 281–289
   Google Scholar
• Maj J, Pirozzi R, Magliano L, Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. American Journal of Psychiatry 1998; 155: 30–35
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Licht R W, Broderson A, et al. Outcome of lithium prophylaxis: a prospective follow-up of affective disorder patients assigned to high and low serum lithium levels. Acta Psychiatrica Scandinavica 1998; 98: 310–315
   PubMed Web of Science ®Google Scholar
• Bowden C L, Calabrese J R, McElroy S L, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Archives of General Psychiatry 2000; 57: 481–489
   PubMed Web of Science ®Google Scholar
• Bowden C L, Calabrese J R, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry 2003; 60: 392–400
   PubMed Web of Science ®Google Scholar
• Calabrese J R, Bowden C L, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry 2003; 64: 1013–1024
   PubMed Web of Science ®Google Scholar
• Goodwin G M, Geddes J R. Latest maintenance data on lithium in bipolar disorder. European Neuropsychopharmacology 2003; 13(Suppl 2)S51–S55
   Google Scholar
• Okuma T. Therapeutic and prophylactic effects of carbamazepine in bipolar disorders. Psychiatric Clinics of North America 1983; 6: 147–174
   Google Scholar
• Lusznat R M, Murphy D P, Nunn C MH. Carbamazepine vs lithium in the treatment and prophylaxis of mania. British Journal of Psychiatry 1988; 153: 198–204
   PubMed Web of Science ®Google Scholar
• Placidi G F, Lenzi A, Lazzerini F, et al. The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 30-year trial in 83 patients. Journal of Clinical Psychiatry 1986; 47: 490–494
   PubMed Web of Science ®Google Scholar
• Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatrica Scandinavica 1992; 85: 114–118
   PubMed Web of Science ®Google Scholar
• Small J G, Klapper M H, Milstein V, et al. Carbamazepine compared with lithium in the treatment of mania. Archives of General Psychiatry 1991; 48: 915–921
   PubMed Web of Science ®Google Scholar
• Watkins S E, Callender K, Thomas D R, et al. The effect of carbamazepine and lithium on remission from affective illness. British Journal of Psychiatry 1987; 150: 180–182
   PubMed Web of Science ®Google Scholar
• Greil W, Kleindienst N, Erazo N, Muller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. Journal of Clinical Psychopharmacology 1998; 18: 455–460
   PubMed Web of Science ®Google Scholar
• Post R M, Leverich G S, Rosoff A S, Altshuler L L. Carbamazepine prophylaxis in refractory affective disorders: a focus on long-term follow-up. Journal of Clinical Psychopharmacology 1990; 10: 318–327
   PubMed Web of Science ®Google Scholar
• Tohen M, Waternaux C M, Tsuang M T. Outcome in mania: a 4-year prospective follow-up of 75 patients utilizing survival analysis. Archives of General Psychiatry 1990; 47: 1106–1111
   PubMed Web of Science ®Google Scholar
• Dardennes R, Even C, Bange F, Heim A. Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders: a meta-analysis. British Journal of Psychiatry 1995; 166: 378–381
   PubMed Web of Science ®Google Scholar
• Bocchetta A, Chillotti C, Severino G, et al. Carbamazepine augmentation in lithium-refractory bipolar patients: a prospective study on long-term prophylactic effectiveness. Journal of Clinical Psychopharmacology 1997; 17: 92–96
   Google Scholar
• Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology 2000; 42(Suppl 11)2–10
   Google Scholar
• Kleindienst N, Greil W. Inter-episodic morbidity and drop-out under carbamazepine and lithium in the maintenance treatment of bipolar disorder. Psychological Medicine 2002; 32: 493–501
   Google Scholar
• Bowden C L. Acute and maintenance treatment with mood stabilizers. International Journal of Neuropsychopharmacology 2003; 6: 269–275
   PubMed Web of Science ®Google Scholar
• Lambert P A, Venaud G. A comparative study of valpromide versus lithium in the prophylaxis of thymic disorders. Nervure 1992; 5.2: 57–65
   Google Scholar
• Macritchie K AN, Geddes J R, Scott J, Haslam D RS, Goodwin G M. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder (Cochrane Review). The Cochrane library. Update Software, Oxford 2002, Issue 2.
   Google Scholar
• Gyulai L, Bowden C L, McElroy S L. Mintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003; 28: 1374–1382
   PubMed Web of Science ®Google Scholar
• Bowden C L, Calabrese J R, McElroy S L, et al. The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. Biological Psychiatry 1999; 45: 953–958
   PubMed Web of Science ®Google Scholar
• Calabrese J R, Bowden C L, McElroy S L, et al. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. American Journal of Psychiatry 1999; 156: 1019–1023
   PubMed Web of Science ®Google Scholar
• Calabrese J R, Bowden C L, Sachs G S, et al. A double-blind, placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry 1999; 60: 79–88
   PubMed Web of Science ®Google Scholar
• Calabrese J R, Suppes T, Bowden C L, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid cycling bipolar disorder. Journal of Clinical Psychiatry 2000; 61: 841–850
   PubMed Web of Science ®Google Scholar
• Calabrese J R, Vieta E, Shelton M. Latest maintenance data on lamotrigine in bipolar disorder. European Neuropsychopharmacology 2003; 13(Suppl 2)S57–S66
   Google Scholar
• Tohen M, Ketter T A, Zarate C A, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. American Journal of Psychiatry 2003; 160: 1263–1271
   PubMed Web of Science ®Google Scholar
• Tohen M, Chengappa K, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabilizer versus mood stabilizer alone. British Journal of Psychiatry 2004; 184: 337–345
   PubMed Web of Science ®Google Scholar
• Tohen M, Bowden C L, Calabrese J R, et al. Olanzapine versus placebo in the prevention of relapse in bipolar disorder. Archives of General Psychiatry in press
   Google Scholar
• Tohen M, Greil W, Calabrese J R, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month randomized, double blind, controlled clinical trial. American Journal of Psychiatry 2005; 162: 1281–1290
   PubMed Web of Science ®Google Scholar
• Altshuler L, Suppes T, Black D, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. American Journal of Psychiatry 2003; 160: 1252–1262
   PubMed Web of Science ®Google Scholar